Several strategies are under investigation, including checkpoint inhibitors that block immune-suppressive pathways like PD-1/PD-L1 [65], chimeric antigen receptor T (CAR T)-cell therapies targeting tumor-specific antigens [23,66], and cancer vaccines [4] to stimulate an anti-tumor immune response. This evidence concerns the gene CD274 and neoplasm.